Crestor (Rosuvastatin) News and Research

RSS

Crestor (Rosuvastatin) is a once-daily prescription medication for use as an adjunct to diet in the treatment of various lipid disorders including primary hypercholesterolemia, mixed dyslipidemia and isolated hypertriglyceridemia. It is a member of the statin (HMG-CoA reductase inhibitors) class of drug therapy.

Crestor (rosuvastatin calcium) shown to significantly reduce major cardiovascular events

New data from the JUPITER study demonstrated that Crestor (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.

10 Nov 2008

Metabolic genes tied to inflammatory predictor of heart disease and stroke risk

Two new studies provide evidence that differences in people's blood levels of C reactive protein (CRP) stem in part from natural variation in known metabolic genes. The researchers report their findings in the May American Journal of Human Genetics, a publication of Cell Press.

24 Apr 2008

Genomas awarded $1.2 million to develop DNA-guided system for management of statin therapy

Genomas, a biomedical company advancing DNA-guided medicine and personalized healthcare, has announced the award of a Fast-Track Phase I-II Small Business Innovation Research (SBIR) Grant totaling $1.2 million.

20 Mar 2008

Abbott and AstraZeneca confirm Phase III clinical trials of Fenofibrate ABT-335 and Crestor as fixed-dose combination

Abbott and AstraZeneca confirmed they will advance the development of Abbott's next-generation fenofibrate ABT-335 and AstraZeneca's CRESTOR (rosuvastatin calcium) in a fixed-dose combination treatment into Phase III clinical trials.

3 Sep 2007

Coated aspirin doesn't guarantee problem-free use

Some people take aspirin without ever having a problem with their stomach. Others develop low-grade stomach pain or get an ulcer.

31 Jul 2007

Statins show extra benefit in raising "good" HDL cholesterol levels

New research suggests that popular statin drugs may not only lower levels of "bad" LDL cholesterol but also raise levels of "good" HDL cholesterol.

7 Feb 2007

Statins slow the progression of aortic valve stenosis

The trial provides the first prospective clinical evidence that aortic valves have an active biology that can be targeted with medical therapy and contradicts research published in 2005 in the New England Journal of Medicine, which concluded statins did not halt the progression of aortic stenosis.

30 Jan 2007

More physicians now visit web sites to find information on brand-name prescription drugs

An increased number of physicians visited Web sites that promote brand-name prescription drugs during the first six months of 2006 to seek information about dosages and side effects, according to a recent Manhattan Research study, the Newark Star-Ledger reports.

18 Sep 2006

Statin drug reverses heart disease

Researchers say a high dose of a cholesterol-lowering statin drug can reverse the build-up of plaque in coronary arteries.

15 Mar 2006

Intensive cholesterol lowering with a statins can partially reverse the buildup of plaque in the coronary arteries

A study presented at the American College of Cardiology's 55th Annual Scientific Session demonstrates, for the first time, that very intensive cholesterol lowering with a statin drug can regress (partially reverse) the buildup of plaque in the coronary arteries.

14 Mar 2006

Statins cut the risk of serious infection

According to scientists Cholesterol-lowering drugs, known as statins, can reduce the risk of severe infection in patients suffering from heart disease or stroke.

26 Jan 2006

Statins account for 81% of first-line therapies for dyslipidemia treatment

Decision Resources, Inc., finds that despite the dominant market position of statins in the treatment of dyslipidemia, only 81% of patients receive a statin as a first-line therapy for the disease.

23 Jan 2006

Drug company proposes FDA check all drug advertising prior to marketing

Drug company AstraZeneca has proposed that it should be a mandatory requirement for pharmaceutical companies to submit all direct-to-consumer advertising to the U.S. Food and Drug Administration for review prior to its use.

2 Nov 2005

Most serious side effects in statins may be higher in one of the newest drugs, rosuvastatin (Crestor)

A post-market analysis of cholesterol-lowering drugs called statins indicates that some of the most serious side effects may be higher in one of the newest drugs, rosuvastatin (Crestor). The drug is the strongest statin available because it has the greatest effect per milligram on low-density lipoprotein ("bad" cholesterol).

26 May 2005

New cholesterol drug Crestor causes safety concerns

A study by a leading medical journal has concluded that AstraZeneca's controversial drug Crestor produces more than twice as many side effects as other common cholesterol lowering treatments.

24 May 2005

New statin study shows arrested progression of atherosclerosis

The first study to use cutting edge magnetic resonance imaging to examine the effect of a statin - rosuvastatin (Crestor) - on the fatty plaques in arteries, was presented yesterday at the 75th European Atherosclerosis Society Congress. ORION revealed that rosuvastatin has a beneficial effect on the size and composition of fatty plaques in arteries (specifically the carotid artery in the neck). Fatty plaques that are vulnerable to sudden rupture can cause heart attacks and strokes without warning.

25 Apr 2005

FDA issues information on the risks and benefits of Crestor

The U.S. Food and Drug Administration (FDA), today issued public health advice, patient information, and professional healthcare information on the risks and benefits of Crestor (Rosuvastatin calcium), a cholesterol-lowering drug.

2 Mar 2005

AstraZeneca reconfirms the safety of Crestor

In the case of Crestor (rosuvastatin calcium), the application for approval was the most extensive ever for a statin involving more than 12,000 patients, and was unanimously recommended for approval by the FDA's advisory board in July of 2003.

20 Nov 2004

FDA Vioxx fiasco raises questions about AIDS drug approvals for developing world

AIDS Healthcare Foundation (AHF), today noted that the current "FDA fiasco" involving the agency's initial approval and subsequent recall of Merck's troubled arthritis drug, Vioxx, raises serious questions about the FDA's ongoing parallel role in the approval of generic AIDS drugs for widespread use in Africa and the developing world.

19 Nov 2004

Cholesterol-lowering drugs can interact with grapefruit juice and increase the risk of the drugs' potential side-effects

Britain's Medicines and Healthcare Products Regulatory Agency recently issued prescribing advice reminding healthcare professionals that certain cholesterol-lowering drugs, namely Zocor (simvastatin) and Lipitor (atorvastatin), can interact with grapefruit juice and increase the risk of the drugs' potential side-effects.

4 Nov 2004